



## Clinical Research Advances in Chronic Lymphocytic Leukemia (CLL)

Guest Editor:

### Prof. Dr. Spencer Gibson

1. CancerCare Manitoba Research Institute, CancerCare Manitoba, Winnipeg, MB, Canada
2. Department of Biochemistry and Medical Genetics, University of Manitoba, Winnipeg, MB, Canada
3. Kipnes Endowed Chair, Department of Oncology, University of Alberta, Edmonton, AB, Canada

Deadline for manuscript submissions:

**closed (30 June 2024)**

### Message from the Guest Editor

In recent years, chronic lymphocytic leukemia (CLL) treatments have altered dramatically. In the past, the frontline therapy for CLL was chemoimmunotherapy, which left many patients with treatment-limiting toxicities. This has changed to targeted therapies, employing. Furthermore, many questions pertaining to how various treatment options may be tailored to the correct patient at the correct time remain unanswered. Beyond treatments, changes in patients' immune systems and in the microenvironment of the bone marrow and lymph nodes are only now coming into focus. Understanding how CLL cells interact in these microenvironments and how treatments might be targeted are key questions for CLL researchers.

We are pleased to invite you to submit your high-quality manuscripts to this Special Issue. The aim of this Special Issue is to focus on clinical advances in CLL treatment and management, as well as changes in the microenvironment of CLL patients. We hope to gather a collection of at least 10 articles. Original research articles and reviews are welcome. We will also accept manuscripts presenting retrospective and prospective clinical observations.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

Cancers Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)